Variation of α-methylacyl-CoA racemase expression in prostate adenocarcinoma cases receiving hormonal therapy

Human Pathology

Volumn 37, Issue 9, 2006, Pages 1186-1192

  Tang, Xiaoyan ^a   Serizawa, Akihiko ^a   Tokunaga, Masatoshi ^a   Yasuda, Masanori ^a   Matsushita, Kazuo ^b   Terachi, Toshiro ^a   Osamura, Robert Yoshiyuki ^a  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOKAI UNIVERSITY TOKYO HOSPITAL   (Japan)

Author keywords

methylacyl CoA racemase; Hormonal therapy; Immunohistochemical study; Prostate adenocarcinoma

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; ANDROGEN; ANDROGEN RECEPTOR; BICALUTAMIDE; CHLORMADINONE ACETATE; FLUTAMIDE; GONADORELIN AGONIST; GOSERELIN; LEUPRORELIN;

ARTICLE; CONTROLLED STUDY; DIGITAL IMAGING; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PROSTATE ADENOCARCINOMA; PROTEIN EXPRESSION; RANK SUM TEST;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS, HORMONAL; HUMANS; IMAGING, THREE-DIMENSIONAL; IMMUNOHISTOCHEMISTRY; MALE; PROSTATIC NEOPLASMS; RACEMASES AND EPIMERASES;

EID: 33747823288     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2006.04.019     Document Type: Article

References (20)

1. Schmitz W., Albers C., Fingerhut R., and Conzelmann E. Purification and characterization of an alpha-methylacyl-CoA racemase from human liver. Eur J Biochem 231 (1995) 815-822
2. Xu J., Stolk J.A., Zhang X., et al. Identification of differentially expressed genes in human prostate cancer using subtraction and microarray. Cancer Res 60 (2000) 1677-1682
3. Suzue K., Montag A.G., Tretiakova M., Yang X.J., and Sahoo S. Altered expression of alpha-methylacyl-coenzyme A racemase in prostatic adenocarcinoma following hormone therapy. Am J Clin Pathol 123 (2005) 553-561
4. Rubin M.A., Bismar T.A., Andren O., et al. Decreased alpha-methylacyl CoA racemase expression in localized prostate cancer is associated with an increased rate of biochemical recurrence and cancer-specific death. Cancer Epidemiol Biomarkers Prev 14 (2005) 1424-1432
5. Kuefer R., Varambally S., Zhou M., et al. Alpha-methylacyl-CoA racemase: expression levels of this novel cancer biomarker depend on tumor differentiation. Am J Pathol 161 (2002) 841-848
6. Rubin M.A., Zhou M., Dhanasekaran S.M., et al. Alpha-methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 287 (2002) 1662-1670
7. Verhoeven N.M., Wanders R.J.A., Poll-The B.T., Saudubray J.-M., and Jakobs C. The metabolism of phytanic acid and pristanic acid in man: a review. J Inherit Metab Dis 21 (1998) 697-728
8. Mobley J.A., Leav I., Zielie P., et al. Branched-fatty acids in dairy and beef products markedly enhance alpha-methylacyl-CoA racemase expression in prostate cancer cells in vitro. Cancer Epidemiol Biomarkers Prev 12 (2003) 775-783
9. Schoonjans K., Staels B., and Auwerx J. Role of the peroxisome proliferators-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res 37 (1996) 907-925
10. Wolfrum C., Ellinghaus P., Fobker M., et al. Phytanic acid is ligand and transcriptional activator for murine liver fatty acid binding protein. J Lipid Res 40 (1999) 708-714
11. Swinnen J.V., van Veldhoven P.P., Esquenet M., Heyns W., and Verhoeven G. Androgens markedly stimulate the accumulation of neutral lipids in the human prostatic adenocarcinoma cell line LNCaP. Endocrinology 137 (1996) 4468-4474
12. Zha S., Ferdinandusse S., Denis S., et al. Alpha-methylacyl-CoA-racemase as an androgen-independent growth modifier in prostate cancer. Cancer Res 36 (2003) 7365-7376
13. Japanese Urological Association and the Japanese Society of Pathology. General rule for clinical and pathological studies on prostate cancer, Chapter 3. 3rd ed. (2001), Kanehara Press, Tokyo (Japan) 90-93
14. Osmundsen H., Bremer J., and Pedersen J.I. Metabolic aspects of peroxisomal beta-oxidation. Biochim Biophys Acta 1085 (1991) 141-158
15. Steineger H.H., Sorensen H.N., Tugwood J.D., Skrede S., Spydevold O., and Gautvik K.M. Dexamethasone and insulin demonstrate marked and opposite regulation of the steady-state mRNA level of the peroxisomal proliferator-activated receptor (PPAR) in hepatic cells. Eur J Biochem 225 (1994) 967-974
16. Zha S., Ferdinandusse S., Hicks J.L., et al. Peroxisomal branched chain fatty acid beta-oxidation pathway is upregulated in prostate cancer. Prostate 63 (2005) 316-323
17. So A.I., Hurtado-Coll A., and Gleave M.E. Androgen and prostate cancer. World J Urol 21 (2003) 325-337
18. Jing C., Beesley C., Foster C.S., et al. Identification of the messenger RNA for human cutaneous fatty acid-binding protein as a metastasis inducer. Cancer Res 60 (2000) 2390-2398
19. van Breda E., Keizer H.A., Vork M.M., et al. Modulation of fatty-acid-binding protein content of rat heart and skeletal muscle by endurance training and testosterone treatment. Plugers Arch 421 (1992) 274-279
20. Knuth U.A., Hano R., and Nieschlag E. Effect of flutamide or cyproterone acetate on pituitary and testicular hormones in normal men. J Clin Endocrinol Metab 59 (1984) 963-969